Last reviewed · How we verify

Ropivacaine Monohydrochloride

Clinique Saint-Jean, Bruxelles · FDA-approved active Small molecule

Ropivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.

Ropivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local and regional anesthesia for surgical procedures, Peripheral nerve blocks, Epidural anesthesia.

At a glance

Generic nameRopivacaine Monohydrochloride
SponsorClinique Saint-Jean, Bruxelles
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve fibers. This prevents depolarization and action potential generation, resulting in loss of sensation in the infiltrated tissue. It has a lower propensity for cardiotoxicity compared to some other local anesthetics due to its preferential blockade of sensory over motor nerves at lower concentrations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: